New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:16 EDTBCLIBrainStorm Cell announces presentation of Phase IIa ALS trial data
BrainStorm Cell announced that interim results from the company's Phase IIa ALS trial conducted at Hadassah Medical Center were presented at the Joint Congress of European Neurology. The positive safety and preliminary efficacy results observed in this study are consistent with results observed in the company's previous Phase I/II trial. Between these two studies, a total of 26 patients have been treated with NurOwn, BrainStorm's stem cell therapy candidate for ALS. The company said, "We are very satisfied with the results observed so far in these two studies. The fact that some of the patients actually demonstrated clinical improvement surpassed our expectations of achieving stabilization or reduced rate of decline. We look forward to the completion of this trial and to building on these results in our double-blind, placebo controlled, multi-center study currently being launched in the USA."
News For BCLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
06:48 EDTBCLIBrainStorm receives $1.1M from Israel's OCS
BrainStorm Cell Therapeutics announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics was awarded a grant of approximately $1.1M from Israel's Office of the Chief Scientist, or OCS. This is the eighth year that BrainStorm has been in receipt of grant support from the Office of the Chief Scientist, which is part of the Ministry of Trade and Industry Program to support innovative technologies in Israel. The funds will support the development NurOwn, BrainStorm's innovative mesenchymal stem cell-based platform for treating neurodegenerative diseases including BrainStorm's phase 2 clinical program in amyotrophic lateral sclerosis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use